Peer Exchange

The Center for Biosimilars® Peer Exchange® peer-to-peer panel discussions feature authoritative insights, opinions, and perspectives on important issues facing today's cancer care professionals.

EP. 1: Biosimilars in Oncology: Addressing Awareness

EP. 2: Current State of Biosimilars: Approval, Availability, and Efficacy

EP. 3: Biosimilars in Oncology: Equivalency and Cost

EP. 4: Are Biosimilar Costs a Factor for Patients?

EP. 5: Biosimilars: Addressing Roadblocks to Market Adoption

EP. 6: Switching to Available Biosimilars in Oncology

EP. 7: Determining Biosimilars' Role in the Formulary

EP. 8: Market-Access Considerations for Biosimilars in Oncology

EP. 9: Where Do Biosimilars Fit in to the Treatment Landscape?

EP. 10: Multiple Biosimilars for a Single-Reference Biologic

EP. 11: Strategies for Incorporating Biosimilars Into Care Plans

EP. 12: Incorporating Biosimilars in Oncology: Working Collaboratively

EP. 13: Economic Impact of Biosimilars in Oncology

EP. 14: Biosimilars in Oncology: Long-Term Financial Benefit

EP. 15: Competition in the Biosimilar Marketplace

EP. 16: Biosimilars in Oncology: Future Directions

EP. 1: Pfizer's Citizen Petition on Biosimilar Communications

EP. 2: Combating Misinformation and Misconceptions About Biosimilars

EP. 3: Targeted Education for Biosimilar Stakeholders

EP. 4: US Versus EU Education on Biosimilars

EP. 5: The FDA's Approach to Biosimilar Education

EP. 6: Biosimilarity, Manufacturing Changes, and Comparability

EP. 7: Clinicians' Understanding of Manufacturing Changes

EP. 8: The Extrapolation of Indications

EP. 9: Selecting the Most Sensitive Population for Confirmatory Trials

EP. 10: Immunogenicity and Biosimilars

EP. 11: Misconceptions About Interchangeability

EP. 12: Clinical Studies for Biosimilars

EP. 13: The Future of US Biosimilars

EP. 14: The Role of Biosimilars in the US Healthcare System

EP. 15: Allowing the US Biosimilars Market to Flourish

EP. 16: Madelaine Feldman, MD: Prescribers' Understanding of Biosimilars

EP. 17: Molly Billstein Leber, PharmD, BCPS, FASHP: Dispelling Misconceptions About Biosimilar Approval and Use

EP. 18: Madelaine Feldman, MD: Physicians' Concerns Regarding Biosimilars

EP. 19: Molly Billstein Leber, PharmD, BCPS, FASHP: Pharmacists' Awareness of Biosimilars

EP. 20: Madelaine Feldman, MD: Practical Considerations for Biosimilars

EP. 21: Molly Billstein Leber, PharmD, BCPS, FASHP: Adoption of and Education on Biosimilars

EP. 22: Molly Billstein Leber, PharmD, BCPS, FASHP: Interchangeability Laws, Substitution, and the Future Role of Biosimilars

EP. 1: Patient Awareness of Biosimilars and Loyalty to Branded Drugs

EP. 2: Patient Savings From Biosimilars

EP. 3: Barriers to Biosimilars for Oncology Patients

EP. 4: Biosimilars, Payers, and Formulary Changes

EP. 5: The Exceptions Process and its Effect on Patients

EP. 6: Patient Education on Coverage for Biologics and Biosimilars

EP. 7: Alternative Payment Models and Patient Care

EP. 8: The Cost of Biologics and Biosimilars

EP. 9: Rebates and Medicare Part D

EP. 10: CMS' Changes to Reimbursement for Biosimilars

EP. 11: Biosimilars, Private Payers, and Pharmacy-Level Substitution

EP. 12: Patient Assistance Programs and Biosimilars

EP. 13: Manufacturers and the Cost of Biosimilars and Biologics

EP. 14: Diversity in Clinical Trials for Biosimilars

EP. 15: The FDA and Diversity in Clinical Trials

EP. 16: Oncology Biosimilars Making a Difference for Patients

EP. 17: Putting Patients at the Center of the Biosimilar Conversation

EP. 1: Biosimilar Interchangeability and Market Share

EP. 2: Interchangeability and Rheumatology Prescribing Practices

EP. 3: Biosimilars, Interchangeability, and Perceptions of Safety

EP. 4: Global Reference Products in Biosimilar Development

EP. 5: Inspection Reports and Proprietary Information

EP. 6: Reforms at the FDA Level

EP. 7: Biosimilars, Formularies, Contracting, and PBMs

EP. 8: Biosimilar Uptake and Health Plans

EP. 9: CMS and Blended Reimbursement Codes

EP. 10: Healthcare Reform Efforts and the BPCIA

EP. 11: State Laws and Biosimilar Substitution

EP. 12: The PTAB's Role in Biosimilar Patent Disputes

EP. 13: The Need for Clarity After <i>Sandoz v Amgen</i>

EP. 14: Upcoming Patent Litigation in Biosimilars

EP. 15: Challenges Ahead for Biosimilars

EP. 1: Adoption of Biosimilars in the United States and Europe

EP. 2: Delivery Systems and the Acceptance of Biosimilars

EP. 3: Cost and Biosimilar Uptake for Oncology

EP. 4: Biosimilar Prescribing and Cost in Rheumatology

EP. 5: Prescribing Behaviors and Biosimilar Substitution

EP. 6: Chronic Therapy and Switching

EP. 7: Physician Understanding of Biologic Manufacturing

EP. 8: Clinical Trial Design With Biosimilars

EP. 9: Post-Market Pharmacovigilance

EP. 10: Patient Awareness of Biosimilar Products

EP. 11: Payer Intervention and Biosimilar Switching

EP. 12: Extrapolation of Indications in Biosimilars

EP. 13: Cost and Biosimilars in Oncology

EP. 14: Competition and Cost for Biosimilars

EP. 15: Cost, Patient Programs, and Access to Biosimilars

EP. 16: Naming and Coding of Biosimilars

EP. 17: State Legislation on Biosimilars and Substitution

EP. 18: Biosimilars in the Next 5 Years

EP. 1: Knowledge Gaps With Biosimilars

EP. 2: Differences Between Biosimilars and Generic Drugs

EP. 3: Approval Process for Biosimilars

EP. 4: Naming of Biosimilars

EP. 5: Clinical Experience With Biosimilars

EP. 6: Use of Biosimilars in Inflammatory Diseases

EP. 7: Cost and Prescribing Considerations for Biosimilars

EP. 8: Variables Affecting Cost for Biosimilars

EP. 9: Formulary Considerations for Biosimilars

EP. 10: Challenges in Discussing Biosimilars With Patients

EP. 11: Clinician Awareness of Future Biosimilars

EP. 12: The Future of Biosimilars and Managing Inflammatory Diseases